Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apta-3
- Development stage
- Preclinical
- Lead developer
- Aptahem
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Apta-3 is a preclinical-stage synthetic RNA aptamer therapeutic being developed by the Swedish biotechnology company Aptahem. It is part of a portfolio of multifunctional aptamers designed to address life-threatening conditions by modulating coagulation, inflammation, and immune system responses. Developed using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method, Apta-3 is intended to bind to specific target molecules with high affinity and specificity. As of current reports, Apta-3 has not yet been activated for active development, manufactured, or studied, and its specific molecular target and primary therapeutic indication remain undisclosed by the developer.
- Other names
- Apta-3-Aptahem-RNA therapeutic (aptamer)
Beyond the preview
Go deeper on Apta-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apta-3.